Dr. Chase is an internationally recognized thought leader in clinical neurology and neurosciences research. His focus has been on the neurodegenerative disorders and their therapy, especially the treatment of Alzheimer’s disease, Parkinson’s disease, and related cognitive and motor disorders. Dr. Chase is the former Scientific Director, Clinical Director, and head of Experimental Therapeutics Branch at the National Institute of Neurological Disorders and Stroke (NINDS). More recently, he founded or co-founded and served as CEO and President of Hamilton Pharmaceuticals and Chase Pharmaceuticals (sold to Allegran Plc for $1,000,000.000.00). Currently, he is CEO and President of Riverside Pharmaceuticals and Chase Therapeutics.
Dr. Chase received his SB from the Massachusetts Institute of Technology, his MD from Yale University School of Medicine, and completed neurology residency at Harvard Medical School and Mass General Hospital. He received postdoctoral training basic and clinical neuropharmacology at the National Institute of Mental Health. He has served as principal investigator on nearly 200 clinical trials, authored more than 80 patents, and published over 500 peer-reviewed papers. Dr. Chase was the founding president of the American Society for Experimental NeuroTherapeutics.
“We are honored to have Dr. Chase as advisor to GT Biopharma’s board of directors. His vast experience of drug development and successful track record of taking drugs to the commercial markets will greatly assist GT Biopharma with its efforts to advance our Neurology technologies thru the FDA process with entry to the commercial markets,” said Executive Chairman Anthony J. Cataldo.
About GT Biopharma, Inc.:
GT Biopharma, Inc. is a biotech company focused on innovative drugs for the treatment of cancer and CNS diseases (Neurology and Pain) along with other unmet medical needs. GT’s lead oncology drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug’s cytotoxic payload. OXS-1550 has demonstrated encouraging results in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-3550 TriKE technology was developed by researchers at the University of Minnesota Masonic Cancer Center. As demonstrated in non-clinical models, this targeted immunotherapy directs immune cells to kill cancer cells while diminishing drug-related toxicity. GT’s CNS platform is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for CNS disease and shepherding the products through the FDA approval process to the NDA. The current CNS pipeline products currently include treatment for neuropathic pain, refractory epilepsies, the symptoms of myasthenia gravis, and motion sickness.
Tel: (310) 788-2850
Email: [email protected]
SOURCE: GT Biopharma Inc.